热门资讯> 正文
Xenon任命Tucker Kelly为CFO
2025-10-16 20:48
- Xenon Pharmaceuticals (NASDAQ:XENE) announced on Thursday the appointment of Tucker Kelly as Chief Financial Officer and member of the Xenon senior executive team.
- Kelly is an executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the company prepare for the anticipated commercialization of its lead candidate, azetukalner.
- Azetukalner is currently being studied broadly in three Phase 3 programs for the treatment of epilepsy, major depressive disorder, and bipolar depression.
- Kelly most recently served as executive vice president, CFO, and treasurer at Deciphera Pharmaceuticals, now a wholly owned subsidiary of Ono Pharmaceuticals.
More on Xenon Pharma
- Xenon Pharmaceuticals Inc. (XENE) Nav1.7 And Kv7 Programs Investor Webinar Transcript
- Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
- Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
- Goldman's 48 potential M&A candidates
- Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs
推荐文章
美股机会日报 | 阿里发布千问3.5！性能媲美Gemini 3；马斯克称Cybercab将于4月开始生产
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
